Balanced news tone
News Sentiment
CRDL sentiment intelligence
Cardiol Therapeutics Inc Class A news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
56
Balanced news tone
42 relevant articles
News tone and price action are not far from neutral.
78/100 classification confidence.
directly relevant articles
high-authority source matches
-3.8% over one week, -1.9% over four weeks, trend inactive, and below fair value.
H.C. Wainwright reiterates Cardiol Therapeutics stock Buy rating at $9
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Primary event
Market update
78/100 classification
One-week reaction
-3.8%
Price reacting lower
Trend fit
Trend inactive
-1.9% over four weeks
Fair value
-24.3%
Below fair value
Value support
Sentiment Mix
Positive, neutral, negative
Positive
15
Neutral
25
Negative
2
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
The Globe and Mail
Direct company coverage
Cardiol Therapeutics Sets June 24, 2026 Date for Annual General Meeting of Shareholders
Cardiol Therapeutics has announced that its Annual General Meeting of Shareholders will be held on June 24, 2026, with May 7, 2026, set as the record date for voting eligibility. The company, a foreign private issuer reporting under Form 40-F, also detailed its use of notice-and-
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 12 Apr 2026 01:39
- Source
- The Globe and Mail
Stock Titan
Direct company coverage
Cardiol Therapeutics (CRDL) sets June 24, 2026 AGM and May 7 record date
Cardiol Therapeutics Inc. (CRDL) has scheduled its Annual General Meeting (AGM) for June 24, 2026, with a record date of May 7, 2026, for both notice and voting rights as well as determining beneficial ownership. The meeting will involve holders of Class A Common shares and will
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 10 Apr 2026 17:09
- Source
- Stock Titan
Stock Titan
Direct company coverage
Cardiol Therapeutics (CRDL) files Form 40-F: 100.26M shares, audited 2025 results
Cardiol Therapeutics Inc. has filed its Annual Report on Form 40-F, which includes its audited financial statements for the fiscal year ended December 31, 2025. The report indicates 100,257,009 shares outstanding and confirms that management assessed internal controls as effectiv
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 01 Apr 2026 09:09
- Source
- Stock Titan
Stock Titan
Direct company coverage
Heart drug trial passes halfway mark as Cardiol funds work into 2027
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 01 Apr 2026 07:00
- Source
- Stock Titan
TradingView
Direct company coverage
Taxes of Cardiol Therapeutics Inc. Class A – HAM:CT9
This article displays tax information for Cardiol Therapeutics Inc. Class A (HAM:CT9). It includes a table with period, value, change, and change percentage data, set against the backdrop of TradingView's financial data and tools. The page seems to be a financial data presentatio
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 26 Mar 2026 19:09
- Source
- TradingView
Market source
Direct company coverage
Cardiol Therapeutics Touts Phase III MAVERIC Timeline for CardiolRx at TD Cowen Healthcare Conference
Cardiol Therapeutics presented at TD Cowen's 46th Annual Healthcare Conference, highlighting the accelerated enrollment of its Phase III MAVERIC study for CardiolRx in recurrent pericarditis, with top-line results expected in the second half of the year. The company emphasized th
- Tone
- Positive 82/100
- Event
- Earnings
- Published
- 08 Mar 2026 15:12
- Source
- Market source
TipRanks
Direct company coverage
Cardiol Therapeutics to Present Cardiovascular Pipeline Update at TD Cowen Health Care Conference
Cardiol Therapeutics will present updates on its cardiovascular pipeline at the TD Cowen 46th Annual Health Care Conference on March 4, 2026. The presentation will highlight progress in its Phase III MAVERIC trial and Phase II ARCHER study, as well as the development of CRD-38. D
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 25 Feb 2026 14:51
- Source
- TipRanks
MarketBeat
Direct company coverage
Cardiol Therapeutics (NASDAQ:CRDL) Receives "Buy" Rating from HC Wainwright
HC Wainwright reaffirmed a "Buy" rating for Cardiol Therapeutics (CRDL), setting a $9.00 price target. The company's lead product, CardiolRx, a CBD-based therapeutic, is in clinical development for myocardial protection and heart failure, with Phase 2 data already reported. Insti
- Tone
- Positive 76/100
- Event
- Analyst action
- Published
- 14 Feb 2026 17:53
- Source
- MarketBeat
Stock Titan
Direct company coverage
Myocarditis trial finds CardiolRx reduced heart swelling marker
Cardiol Therapeutics announced the publication of its Phase II ARCHER study results in ESC Heart Failure, revealing that CardiolRx significantly reduced left ventricular mass and showed favorable trends in myocardial inflammation markers in 109 patients with acute myocarditis. Th
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 11 Feb 2026 11:27
- Source
- Stock Titan
MarketBeat
Direct company coverage
Cardiol Therapeutics (NASDAQ:CRDL) Raised to Strong-Buy at Brookline Capital Management
Brookline Capital Management has upgraded Cardiol Therapeutics (NASDAQ:CRDL) to a "strong-buy" rating. The company, which specializes in immunomodulatory cardiovascular therapies, reported quarterly EPS of ($0.09) and has an average target price of $9.00 from analysts, indicating
- Tone
- Positive 66/100
- Event
- Analyst action
- Published
- 06 Feb 2026 14:52
- Source
- MarketBeat
Market source
Direct company coverage
Cardiol Therapeutics Reports Results of 2025 Annual General Meeting of Shareholders
Cardiol Therapeutics Inc. announced the results of its 2025 Annual General Meeting of Shareholders, where all Management resolutions were approved. Dr. Timothy Garnett was elected to the Board of Directors, bringing extensive drug development and commercial expertise to the compa
- Tone
- Positive 75/100
- Event
- Earnings
- Published
- 01 Feb 2026 00:32
- Source
- Market source
Market source
Direct company coverage
Analysts Expect Breakeven For Cardiol Therapeutics Inc. (TSE:CRDL) Before Long
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 12 Jan 2026 08:00
- Source
- Market source